Results 121 to 130 of about 13,388,827 (299)
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
Journal of Diabetes Research, 2016 Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4
Sevin Demir +2 more
doaj +1 more source
Journal of the Science of Food and Agriculture, EarlyView.Abstract INTRODUCTION Bromelain, a complex mixture of proteolytic enzymes primarily extracted from plants of the Bromeliaceae family, has gained prominence because of its broad industrial applicability, particularly in the food, pharmaceutical and cosmetic sectors.
Genésio José da Silva Neto +6 more
wiley +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo +12 more
wiley +1 more source
, 2016 Unchalee Permsuwan,1 Piyameth Dilokthornsakul,2 Surasak Saokaew,2–4 Kednapa Thavorn,5–7 Nathorn Chaiyakunapruk2,4,8,9 1Faculty of Pharmacy Chiang Mai University, Chiang Mai, 2Center of Pharmaceutical Outcomes Research, Faculty of ...
Chaiyakunapruk N +4 more
core
Phytotherapy Research, EarlyView.Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng +6 more
wiley +1 more source
Screening Emodin Derivatives as DPP-4 Inhibitor Candidates: In Silico and In Vitro Assessment [PDF]
Diabetes mellitus (DM) is a chronic metabolic disease distinguished by disrupted glucose metabolism, causing elevated blood sugar levels. One of the latest therapeutic strategies involves inhibiting dipeptidyl peptidase-4 (DPP-4) to regulate glucose ...
Syahbirin, Gustini +3 more
core +1 more source
Phytotherapy Research, EarlyView.Functional dyspepsia involves duodenal barrier dysfunction, low‐grade immune activation and altered neuroimmune signalling. Various plant‐derived bioactives may modulate PPAR signalling, reduce inflammatory and oxidative stress, and support epithelial, immune, metabolic, and sensory homeostasis.
Irene Palenca +5 more
wiley +1 more source
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
Diabetes, Metabolic Syndrome and Obesity, 2013 Baptist GallwitzDepartment of Medicine IV, Eberhard-Karls-University Tübingen, Tübingen, GermanyAbstract: The first dipeptidyl-peptidase-IV (DPP-4) inhibitor for the treatment of type 2 diabetes became available in 2006. Since then, the
Gallwitz B
doaj
Role of DPP-4 inhibitors in the treatment of type 2 Diabetes
, 2014 Dipeptidyl peptidase 4 (DPP-4) inhibitors are a relatively new class of oral anti-hyperglycaemic medication which enhance insulin secretion. They are considered to be a promising drug class that may meet the demands for efficacy in the treatment of type ...
Nguyen, Khanh Minh
core
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
, 2016 Diabetes mellitus (DM) is a chronic disease which caused around 1.5 million deaths in 2012. Type 2 diabetes mellitus (T2DM) accounts for 90% of DM worldwide. The prevalence of T2DM is increasing due to obesity.
Kristin, Erna
core +1 more source